Loading...
•
Sep 30, 2023
QuantumScape Q3 2023 Earnings Report
QuantumScape reported progress in customer prototype testing, manufacturing scale up, and strategic outlook.
Key Takeaways
QuantumScape reported progress in customer prototype testing, highlighting a top-performing A0 prototype cell achieving over 1,000 full cycle equivalents with over 95% discharge energy retention. The company is focused on QSE-5 development and collaborating with a prospective automotive launch customer. They ended Q3 with over $1.1B in liquidity and forecast their cash runway will extend into 2026.
Top-performing A0 prototype cell achieved over 1,000 full cycle equivalents with over 95% discharge energy retention.
Collaborating with a prospective launch customer in the automotive sector for QSE-5.
Entered into a technology evaluation agreement with a leading global consumer electronics player.
Process qualification of Raptor equipment began on schedule.
QuantumScape
QuantumScape
Forward Guidance
QuantumScape maintains its full-year 2023 guidance on cash operating expenses of $225M to $275M and revises its capex guidance to $75M to $100M. The company continues to target low-volume B samples in 2024 off our Raptor process and higher-volume B samples in 2025 off our Cobra process. They now forecast that their cash runway will extend into 2026.
Positive Outlook
- Targeting low-volume B samples in 2024 off Raptor process.
- Targeting higher-volume B samples in 2025 off Cobra process.
- Cash runway extended into 2026.
- Focus on process and defect control.
- Focus on equipment and data automation.
Challenges Ahead
- Significant challenges remain in producing cells in large volumes with high quality and reliability.
- The company faces significant challenges in its attempts to develop a solid-state battery cell and produce it at high volumes.
- The Company could encounter significant delays and/or technical challenges in replicating the performance seen in its single-layer and early multilayer cells.
- The Company has encountered delays and other obstacles in acquiring, installing and operating new manufacturing equipment for automated and/or continuous-flow processes.
- Delays or difficulties in meeting technical milestones or scaling up QS-0 could cause prospective customers and joint venture partners not to purchase cells from our pre-production line or not to proceed with a manufacturing joint venture.